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Summary

Contemporary LVADs and VA Risk

Advanced heart failure represents a significant strain on our health care system and is
associated with increased morbidity and mortality. New device therapies, including left
ventricular assist device (LVAD) implantation, have transformed management as both a
destination therapy and as a bridge to transplantation. Although LVADs have improved patient
outcomes, arrhythmias represent a significant and costly complication of this therapy. In recent
years, implantable cardioverter-defibrillators (ICDs) have been developed to reduce the incidence
of lethal arrhythmia. However, a gap in the literature exists for both guidelines in prevention of
early ventricular arrhythmia (VA) in LVAD recipients and the effectiveness of ICDs when paired
with various LVADs. Here, we clarify these guidelines and show that ICD selection should be
tailored to the type of LVAD. We also show that subcutaneous ICDs represent an attractive
alternative option for certain cohorts of patients, although transvenous ICDs remain a first-line
choice at this time. Ultimately, understanding the various management options that affect
outcomes in heart failure patients is important for treatment and clinical decision-making in an
ever-growing population.
Methods: PubMed was searched for various studies published from January 2001 through
December 2020, using subject terms “implantable cardioverter-defibrillator” OR “ICD” AND
“acute heart failure”, “left ventricular assist device” OR “LVAD” AND “acute heart failure”,
“HeartWare OR HVAD”, “HeartMate II” OR “HMII”, “HeartMate 3” OR “HMIII”,
“Transvenous ICD” OR “TV-ICD” and “subcutaneous ICD” OR “S-ICD”. Authors included case
reports and series, retrospective and prospective studies, systematic reviews and meta-analyses,
clinical guidelines, and narrative reviews. This PubMed search only included studies published in
English and those with human subjects. Initial literature search revealed over 442 articles.
References in the articles were also evaluated for discovery of potentially relevant studies.
Authors reviewed relevant articles and decided which studies to include for this review, with a
concentration on acute HF-relevant articles. A total of 39 resources were selected for inclusion in
this review.

Ventricular Arrhythmias in LVAD Patients
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Figure 1: Diagram of LVAD .1 Left
ventricular assist devices are now
commonly used in advanced HF to
improve survival and reduce mortality.
LVADs are used as both destination
therapy (DT) and as a bridge to heart
transplantation
(BTT).
LVAD
implantation has been shown to result
in prolonged ventricular repolarization,
myocardial scarring and acute
ventricular unloading, all of which
have been shown to predispose
patients to arrhythmias.1,2
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Table 1: Summary of VA in LVAD
Recipients. These data
demonstrate that while
HeartMate III (HMIII) recipients
have a risk for VA after
implantation, it is lower than
patients who have been
implanted with HeartMate II
(HMII) or Heartware (HVAD),
which suggests that the HMIII is
less irritable to the heart.7,8
Although no definitive
conclusions have been reached in
any study, possible reasons for
this difference include
differences in pump size,
increased width of blood-flow
pathways in HMIII, and HMIII’s
intrinsic pulsatility diminishing
shear stress and stasis of blood.8

†: HeartMate II, ‡: HeartMate III, §: Ventricular Arrythmia, ||: Ventricular Fibrillation, #: Ventricular
Tachycardia

ICD Therapy and Types of Devices
ICDs have transformed the management of HF patients by reducing the incidence of lethal arrhythmias and the
risk of SCD.9,10 There are two main types of ICD devices, a transvenous ICD (TV-ICD) and subcutaneous ICD (SICD), which may have different implications in LVAD patients. LVADs can cause electromagnetic interference
(EMI), leading to sensing dysfunction in the S-ICD. However, EMI is more associated with HVAD and HMIII,
with fewer cases occurring in concomitant S-ICD and HMII use.10
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Prospective, randomized trials directly comparing VA incidence in HVAD, HMII, and HMIII
Further investigation and refinement of S-ICD sensing algorithm when used with different
LVADs
Randomized trial data in both BTT and DT patients to determine optimal device indications in
LVAD patients at risk of VA.
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Figure 5: Flow diagram of early VA prevention in LVAD recipients
LVADs represent an important therapy for management of acute and chronic HF,
however, they carry the risk of post-implantation VA. The HMIII appears to have the
lowest risk of VA among its recipients (Table 1).
ICD for primary prevention of early post-VAD VAs should be considered at the time of
LVAD implantation in patients who present with acute HF or risk factors for early VA . Prior to
ICD use, pharmacological therapy may be attempted, however, post-LVAD VAs often fail to
respond to antiarrhythmics. Despite the inherent risk associated with transvenous leads, TVICD should be considered a first-line treatment modality at present until the role of S-ICD is
further evaluated in larger studies. S-ICD may be a viable option in patients with an
exceptionally high risk of bloodstream infection or in patients with prior HMII use.

LVAD (pump)

unit and LVAD

Co ntrol unil

ICD Therapy

First-line

Connector

'¾c:--

Failure

Figure 2: Number of early VA
events. 3 In a group of 162 patients,
24% experienced at least one early VA.
Among patients who experienced an
early VA, 34% underwent more than
one event. Preoperative VA was the
biggest clinical predictor of early VA;
non-ischemic cardiomyopathy and
advanced age were also statistically
significant predictors for VA.3

Figure 3: Types of ICDs
(A)TV-ICD and LVAD Diagram. TV-ICD and LVAD position in the chest. Left, Anterior view. Right, Lateral
view. Advantages of the TV-ICD include the ability to deliver long-term bradycardia pacing and deliver antitachycardiac pacing .
(B) S-ICD and LVAD Diagram. S-ICD and LVAD position in the chest. Left, Anterior view. Right, Lateral view.
Advantages of the S-ICD involve avoidance of an invasive procedure along with intravascular lead-related
problems such as endocarditis and bacteremia.

Current Approach to ICD use in LVAD Patients
\IT-lVAD
Viriables
V -V/VJ nor to ILVAD im~1anta1ion
T Ttiera~y; noACE,ln~~itor pos~lVAO

S
re.
. oo...
2il'tiints
~ ooints

Fail.urn tluraliMjl! I 2mon!ns)
Vk. pDSl LVAD 1lmplantallon -:;30 da1s
Alr1ielfihiril !aman pli[lr!o ILVAD
l~IQl)athK: Ollaloo ~rdlornyQl)alhy
~l~1im1Jrm s«ire

.2~ints:
~ ~lnts
1poinl
1polnl
10 p0ir1~

I.

V
A
o,

I

'

Figure 4: VT-LVAD score . 12 The ASSIST-ICD study used
the results of their observational study assessing the clinical
predictors of late VA to create a score to stratify patient risk,
the “VT-LVAD score”.12 They stated that high-risk and very
high-risk patients should be considered for ICD therapy,
while low-risk patients may consider forgoing ICD
implantation due to the presence of a similar complication
risk profile and a lower potential benefit. Although this
study gives indications for the prevention of late VA, it
takes no position on the prevention of early VA.

1.

“Left Ventricular Assist Device (LVAD).” Mayo Clinic, Mayo Foundation for Medical Education and Research,
www.mayoclinic.org/tests-procedures/ventricular-assist-device/multimedia/left-ventricular-assist-device/img-20006714.
2. Pecha S, Wilke I, Bernhardt A, et al.: Clinical experience of combined heartware ventricular assist device and implantable
cardioverter defibrillator therapy. J Cardiovasc Electrophysiol 2014; .
3. Garan AR, Levin AP, Topkara V, et al.: Early post-operative ventricular arrhythmias in patients with continuous-flow left
ventricular assist devices. J Hear Lung Transplant 2015; .
4. Mosterd A, Cost B, Hoes AW, et al.: The prognosis of heart failure in the general population: The rotterdam study. Eur Heart J
2001;
5. Chia PL, Foo D: Overview of implantable cardioverter defibrillator and cardiac resynchronisation therapy in heart failure
management. Singapore Med. J. 2016,.
6. Chieng D, Paul V, Denman R: Current Device Therapies for Sudden Cardiac Death Prevention – the ICD, Subcutaneous ICD and
Wearable ICD. Hear Lung Circ [Internet] 2019; 28:65–75.
7. Enriquez AD, Calenda B, Miller MA, Anyanwu AC, Pinney SP: The role of implantable cardioverter-defibrillators in patients with
continuous flow left ventricular assist devices. Circ Arrhythmia Electrophysiol 2013; .
8. Mehra MR, Uriel N, Naka Y, et al.: A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report. N Engl J Med
2019; .
9. Biton Y, Baman JR, Polonsky B: Roles and indications for use of implantable defibrillator and resynchronization therapy in the
prevention of sudden cardiac death in heart failure. Heart Fail Rev 2016; .
10. Lewis GF, Gold MR: Safety and Efficacy of the Subcutaneous Implantable Defibrillator. J Am Coll Cardiol [Internet] 2016;
67:445–454. Available from: http://www.sciencedirect.com/science/article/pii/S0735109715074793
11. Black-Maier E, Lewis RK, Barnett AS, et al.: Subcutaneous implantable cardioverter-defibrillator troubleshooting in patients with
a left ventricular assist device: A case series and systematic review. Hear Rhythm 2020; .
12. Galand V, Flécher E, Auffret V, et al.: Predictors and Clinical Impact of Late Ventricular Arrhythmias in Patients With ContinuousFlow Left Ventricular Assist Devices. JACC Clin Electrophysiol 2018; .

